Tumor targeting using anti-her2 immunoliposomes

Journal of Controlled Release

Volumn 74, Issue 1-3, 2001, Pages 95-113

  Park, J W ^a   Kirpotin, D B ^b   Hong, K ^b   Shalaby, R ^b   Shao, Y ^b   Nielsen, U B ^a   Marks, J D ^a   Papahadjopoulos, D ^b   Benz, C C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

ErbB2; HER2; Immunoliposomes; Liposomes

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DAUNOSOME; DOXORUBICIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLIPOSOME; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HER2; NSC 701315; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LIBRARY; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CARDIOTOXICITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; DRUG UPTAKE; ELECTRON MICROSCOPY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR LOCALIZATION; TUMOR REGRESSION; XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; DOXORUBICIN; DRUG STABILITY; GENE THERAPY; GENES, ERBB-2; HUMANS; IMMUNOGLOBULIN FRAGMENTS; LIPOSOMES; NEOPLASMS; RATS;

EID: 0035816199     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(01)00315-7     Document Type: Conference Paper

References (52)

1. The ErbB signaling network: Receptor heterodimerization in development and cancer
2. ErbB2 overexpression in breast cancer: Biology and clinical translation
3. Human breast cancer: Correlation of relapse and survival with amplification of HER2/neu oncogene
4. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
5. The role of immunohistochemistry and fluorescence in situ hybridization for HER-2/neu in assessing the prognosis of breast cancer
6. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues
7. Stability of HER-2/neu expression over time and at multiple metastatic sites
8. Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells
9. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties
10. Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model
11. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis
12. Tumor-antigen heterogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease
13. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product
14. Anti-p185HER2 monoclonal antibodies: Biological properties and potential for immunotherapy
15. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
16. Humanization of an anti-p185HER2 antibody for human cancer therapy
17. HER2 monoclonal antibody in patients with HER/neu-overexpressing metastatic breast cancer
18. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
19. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
20. The carrier potential of liposomes in biology and medicine
21. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo
22. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes
23. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts
24. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma
25. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS
26. Liposomes revisited
27. Immunoliposomes for cancer treatment
28. Development of anti-p185HER2 immunoliposomes for cancer therapy
29. Sterically stabilized anti-HER2 immunoliposomes: Design and targeting to human breast cancer cell in vitro
30. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library
31. Targeting of breast tumors with scFv antibodies selected for internalization from a phage display library
32. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site
33. X-ray structures of fragments from binding and nonbinding versions of a humanized anti-CD18 antibody: Structural indications of the key role of VH residues 59 to 65
34. Endocytosis of liposomes by macrophages: Binding, acidification and leakage of liposomes monitored by a new fluorescence assay
35. Should HER2 status be routinely measured for all breast cancer patients?
36. c-erbB-2 expression and response to adjuvant chemotherapy in women with node-positive early breast cancer
37. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
38. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
39. Cardiotoxicity in patients receiving trastuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artifact?
40. Anti-HER2 immunoliposomes: Enhanced efficacy via intracellular delivery
41. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphiphilic weak bases
42. Pharmacodynamic and pharmacokinetic advantages of anti-p185HER2 immunoliposomes
43. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times
44. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
45. Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing breast cancer xenografts
46. Anti-HER2 immunoliposomes produced by spontaneous capture of an amphipathic poly(ethylene glycol)-anti-HER2 antibody conjugate into the liposome membrane
47. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors
48. Stealth liposomal vinorelbine: Synthesis, stability, and antitumor activity against human breast and lung cancer xenografts
49. Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides
50. Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly(ethylene glycol)-phospholipid conjugates for efficient in vivo gene delivery
51. Anti-HER2 immunoliposome-ribozyme constructs mediate targeted gene transfer and HER2 downmodulation
52. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function